InvestSMART

Immutep Limited (ASX: IMM) - Announcements

Current share price for IMM : $0.021 0.002 (8.70%)+

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Immutep Quarterly Activities Report & Appendix 4C 19 Apr 2021 9:40AM $0.440 $0.021 fallen by 95.23%
$31 Immutep receives A$1,155,055 R&D Tax Incentive 16 Apr 2021 5:46PM $0.440 $0.021 fallen by 95.23%
$31 Immutep Investor Update 14 Apr 2021 9:25AM $0.450 $0.021 fallen by 95.33%
$31 Immutep achieves Fast Track designation for Efti from US FDA 8 Apr 2021 7:52AM $0.440 $0.021 fallen by 95.23%
$31 Immutep announces European Patent Grant for LAG525 7 Apr 2021 8:28AM $0.425 $0.021 fallen by 95.06%
$31 Change in substantial holding 1 Apr 2021 8:22AM $0.405 $0.021 fallen by 94.81%
$31 Appendix 2A 18 Mar 2021 10:59AM $0.370 $0.021 fallen by 94.32%
$31 Immutep collaborates with MSD for phase 2b head & neck trial 16 Mar 2021 8:17AM $0.335 $0.021 fallen by 93.73%
$31 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $0.335 $0.021 fallen by 93.73%
$31 Immutep secures second US patent grant for eftilagimod alpha 9 Mar 2021 4:14PM $0.330 $0.021 fallen by 93.64%
$31 Immutep expands Part B of TACTI-002 collaboration trial 5 Mar 2021 8:21AM $0.315 $0.021 fallen by 93.33%
$31 Half Yearly Report and Accounts 23 Feb 2021 4:23PM $0.380 $0.021 fallen by 94.47%
$31 Immutep Corporate Presentation 2 Feb 2021 8:22AM $0.395 $0.021 fallen by 94.68%
$31 Phase II study for eftilagimod alpha in COVID-19 advances 27 Jan 2021 8:59AM $0.415 $0.021 fallen by 94.94%
$31 Immutep Quarterly Activities Report & Appendix 4C 22 Jan 2021 8:57AM $0.430 $0.021 fallen by 95.12%
$31 Ulcerative Colitis Phase II Study of GSK2831781 Discontinued 22 Jan 2021 8:54AM $0.430 $0.021 fallen by 95.12%
$31 Recruitment of head & neck cancer patients completed for ph2 7 Jan 2021 9:33AM $0.405 $0.021 fallen by 94.81%
$31 Resignation and Appointment of Joint Company Secretary 4 Jan 2021 4:32PM $0.415 $0.021 fallen by 94.94%
$31 Change in substantial holding 4 Jan 2021 9:16AM $0.415 $0.021 fallen by 94.94%
$31 Appendix 2A 31 Dec 2020 12:11PM $0.420 $0.021 fallen by 95%
$31 Change in substantial holding 31 Dec 2020 8:25AM $0.420 $0.021 fallen by 95%
$31 Change in substantial holding 30 Dec 2020 8:22AM $0.390 $0.021 fallen by 94.62%
$31 Immutep granted US patent for eftilagimod alpha with a PD-1 30 Dec 2020 8:20AM $0.390 $0.021 fallen by 94.62%
$31 Change in substantial holding 29 Dec 2020 8:33AM $0.390 $0.021 fallen by 94.62%
$31 Change of Director's Interest Notice - Dr Howard 24 Dec 2020 3:04PM $0.390 $0.021 fallen by 94.62%

501 - 525 of 798 results

Page 21 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.